Prof.(PI).Dr.med. Adam Czaplinski

Neurologie FMH

Dr Med Adam Czaplinski Neurologie Fmh

Prof.(PI).Dr.med. Adam Czaplinski ist Facharzt für Neurologie FMH und renommierter Spezialist für Multiple Sklerose. Zu seinen Spezialgebieten zählen zudem neuromuskuläre Erkrankungen und Polyneuropathien.

Prof. Adam Czaplinski studierte Medizin in Danzig und in Basel und absolvierte seine Ausbildung zum Neurologen grösstenteils an der Neurologischen Universitätsklinik in Basel (Prof. Andreas Steck und Prof. Ludwig Kappos), wo er über mehrere Jahre als Oberarzt und, zuletzt als Leiter der Neurologisch-Neurochirurgischen Poliklinik tätig war. Prof. Czaplinski bildete sich weiter in den USA im Department of Neurology, Baylor College of Medicine und im Methodist Neurological Institute (Prof. Stanley Appel) in Houston, Texas und habilitierte sich nach seiner Rückkehr an der Universität Basel.

Zusätzlich zu seinen Praxisaktivitäten in Zürich, Aarau und Basel ist er auch als Assoziierter Arzt in der Neurologischen Universitätsklinik des Universitätsspitals Basel und als Beleg- und Konsiliararzt in mehreren Hirslanden Kliniken (Klinik Hirslanden Zürich, Hirslanden Klinik Im Park Zürich, Hirslanden Klinik in Aarau, Andreasklinik in Cham) tätig. Professor Czaplinski ist Autor einer Vielzahl von wissenschaftlichen Publikationen und Mitglied der Schweizerischen, Europäischen und Amerikanischen Neurologischen Fachgesellschaften.

Alle schliessen

Seit 2009
Ärztlicher Leiter Neurozentrum Bellevue in Zürich. Praxistätigkeit im Neurozentrum Enge Zürich und Neurozentrum Aarau. Belegarzt in mehreren Hirslanden Kliniken (Klinik Hirslanden Zürich, Hirslanden Klinik Im Park Zürich, Hirslanden Klinik in Aarau, Andreasklinik in Cham)
2008 – 2009
Leiter a. i. Neurologisch-Neurochirurgische Poliklinik, Universitätsspital Basel
2002 – 2008
Oberarzt Neurologie, Universität Basel
2003 – 2005
Postdoctoral fellow am Department of Neurology, Baylor College of Medicine und Methodist Neurological Institute, Houston, Texas, USA
1999 – 2002
Assistenzarzt Neurologie, Universität Basel
1998 – 1999
Assistenzarzt Neurochirurgie, Kantonsspital Aarau
1997 – 1998
Assistenzarzt Neurologie/Neurorehabilitation, Rehaklinik Rheinfelden
1995 – 1997
Assistenzarzt Neurologie/Innere Medizin, Schweizer Paraplegikerzentrum, Basel
1994 – 1995
Assistenzarzt Innere Medizin, Kantonsspital Bruderholz, Basel

2010 – 2018
Mitglied des wissenschaftlichen Beirats der Schweizerischen Multiple Sklerose Gesellschaft
2008 – 2011
Vizepräsident der Schweizerischen Gesellschaft für Muskelkranke (SGMK)
2007
Habilitation, Universität Basel
2003
Fähigkeitsausweis Elektroenzephalographie (EEG) der SGKN
2003
Fähigkeitsausweis Elektroneurographie und Elektromyographie (ENMG) der SGKN
2002
Facharzt für Neurologie FMH
2001
Dissertation: Predictive value of T2-lesion volume for the natural course of multiple sclerosis. Universität Basel, Prof. Dr. Ludwig Kappos
1987 – 1994
Studium der Humanmedizin, Medical University of Gdansk, Polen und Universität Basel, Schweiz

Auszeichnungen

  • Recipient of the Sheila Essey Fellowship Award for ALS Research
  • Fellow of the Swiss National Science Foundation
  • Fellow of the Fonds zur Förderung des Akademischen Nachwuchses der Universität Basel
  • Fellow of the Houston Endowment

  • Schweizerische Neurologische Gesellschaft (SNG)
  • Schweizerische Gesellschaft für Klinische Neurophysiologie (SGKN)
  • European Neurological Society (ENS)
  • American Academy of Neurology (AAN)
  • Polish Neurological Society (PTN)
  • Schweizerische Multiple Sklerose Gesellschaft (SMSG), Wissenschaftlicher Beirat bis 2018
  • Schweizerische Gesellschaft für Muskelkranke (SGMK)
  • Verbindung der Schweizer Ärztinen und Ärzte (FMH)

  • Deutsch
  • Englisch
  • Polnisch
  • Russisch

Prof. Adam Czaplinski ist regelmässig Referent an neurologischen Kongressen in Europa und Amerika und Autor zahlreicher Publikationen.

Ocrelizumab in Switzerland – first experiences
Swiss Federation of Clinical Neurosocieties SFCNS, September 2017
Interlaken/Switzerland

TGA: an altitude sickness?
European Academy of Neurology, June 2017
Amsterdam/Netherlands

Real-life long-term effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohort
American Academy of Neurology, April 2017
Boston/USA

Final results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with RR-MS (SWISSASCENT)
ECTRIMS, September 2016
London/UK

Role of Family Planning in Women of Child-Bearing Age with Multiple Sclerosis (MS) in Switzerland: Results of the Women with MS (WWMS) Patient Survey
American Academy of Neurology April 2016
Vancouver/Canada

Alemtuzumab: real life experience in Switzerland
Swiss Federation of Clinical Neurosocieties SFCNS, November 2015
Bern/Switzerland

Fingolimod treatment induces changes in NK and T helper cell subpopulations and in T cell co-stimulation markers.
ECTRIMS, October 2015
Barcelona/Spain

Stem cells for Amyotrophic Lateral Sclerosis.
European Academy of Neurology Meeting, June 2015
Berlin/Germany

Adherence and compliance in MS therapy.
Polish Neurological Society, March 2015
Lodz/Poland

Alemtuzumab: restoring the immune system.
Swiss Neurological Society, October 2014
Interlaken/Switzerland

Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT).
German Neurological Society, September 2014
Munich/Germany

Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis.
ECTRIMS/ACTRIMS Congress, September 2014
Boston/USA

Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT).
European Neurological Society Congress, June 2014
Istanbul/Turkey

Prolonged-release fampridine in multiple sclerosis: improved ambulatory function by subject-specific changes of the walking pattern.
American Academy of Neurology Congress, Mai 2014
Philadelphia/USA

Swiss post marketing surveillance monitoring quality of life and treatment.
Journées de Neurologie de Langue Française, April 2014
Strasbourg/France

Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT)
ECTRIMS Congress, October 2013
Copenhagen/Denmark

Therapie der Multiplen Sklerose: vom Cortison zur differenzierten Immunomodulation.
13th Swiss-Russian general Practicioners Conference, Mai 2013
St. Petersburg/Russia

Tysabri in der Behandlung der Multiplen Sklerose
MS State of The Art 2013, March 2013
Lodz/Poland

Novel electrochemiluminescence based immunoassay: neurofilament light chain in serum as a marker of axonal damage
William Harvey Day, Queen Mary University, October 2012
London/United Kingdom

A Swiss best practice experience in three different clinical settings of the 6 hour fingolimod observation procedure.
ECTRIMS Congress, October 2012
Lyon/France

Utilization of JC-Virus antibody testing in clinical practice.
ECTRIMS Congress, October 2012
Lyon/France

Tysabri: new data to efficacy and safety.
Central European Tysabri Advisory Board (CETAB) Meeting, October 2012
Vienna/Austria

Fingolimod in daily practice.
Swiss Neurological Society (SNG) Meeting, Mai 2012
Lugano/Switzerland

Update on current treatment strategies in MS
American Academy of Neurology (AAN) Meeting, participant, April 2012
New Orleans/USA

Tysabri: efficacy and safety update.
Central European Tysabri Advisory Board (CETAB) Meeting, January 2012
Bratislava/Slovakia

Personalized treatment strategies in Multiple Sclerosis.
ECTRIMS Congress, October 2011
Amsterdam/Netherlands

Treatment failure: what to do?
MS State of the Art, January 2011
Lucerne/Switzerland

MS therapy update.
ECTRIMS Congress, October 2010
Göteborg/Sweden

Current therapeutic strategies in MS.
European Neurological Society Congress (participant), June 2010
Berlin/Germany

Oral laquinimod for Multiple Sclerosis.
TEVA Symposium, Mai 2010
Jerusalem/Israel

The effect of IFNbeta 1b treatment on cognition in Multiple Sclerosis.
Advisory Board meeting, March 2010
Rome/Italy

Treatment failure, what to do?
Multiple Sclerosis State of the Art, Januar 2010
Luzern/Switzerland

Safety overview of fingolimod.
Fingolimod Advisory Board, December 2009
Berlin/Germany

New oral agents in the therapy of Multiple Sclerosis.
Cladribine Advisory Board, November 2009
Amsterdam/Netherlands

Phasenadaptierte Therapie der Multiplen Sklerose.
182. Tagung der Schweizerischen Neurologischen Gesellschaft, Juni 2009
Interlaken/Switzerland

Application of the Database Controls in Experimental Trials.
Annual Meeting of St.Lukes Hospital, April 2009
Tokyo/Japan

ALS: Can We Predict the Course of Disease?
19. Kongress des Wissenschaftlichen Beirates der DGM, March 2009
Darmstadt/Germany

Natalizumab in daily practice- risks and benefits.
11th State of the Art Symposium, January 2009
Berne/Switzerland

Strategien zur Optimierung der immunomudulatorischen Therapie der MS.
Zürcher MS-Roundtable, Oktober 2008
Zurich/Switzerland

Moderne Therapie der Multiplen Sklerose
Quadrimed Kongress, Mai 2008
Crans Montana/Switzerland

Reconsidering clinical outcomes: relapses, impairment, disability and beyond.
Symposium of the European Charcot Foundation, November 2007
Fiuggi/Italy

Length of prediagnostic period as a predictor of rate of disease progression and survival in ALS.
17th Meeting of the European Neurological Societ, June 2007
Rhodes/Greece

Slower disease progression and prolonged survival in contemporary ALS patients: is the natural history of ALS changing?
177. Tagung der Schweizerischen Neurologischen Gesellschaft, Oktober 2006
Interlaken/Switzerland

Amyotrophic Lateral Sclerosis: Can We Predict the Course of Disease?
Kongress der Polnischen Neurologischen Gesellschaft, September 2006
Krakow/Poland

Predictability of disease progression in amyotrophic lateral sclerosis.
XVIth Meeting of the European Neurological Society, Mai 2006
Lausanne/Switzerland

Slower disease progression and prolonged survival in contemporary ALS patients: is the natural history of ALS changing?
58th Annual Meeting of American Academy of Neurology, April 2006
San Diego/USA

Predictability of disease progression in amyotrophic lateral sclerosis.
16th International Symposium on ALS/MND, December 2005
Dublin/Ireland

Amyotrophic lateral sclerosis: early predictors of prolonged survival.
World Congress of Neurology, November 2005
Sydney/Australia

Application of the Database Controls in Experimental Trials for Amyotrophic Lateral Sclerosis.
57th Annual Meeting of American Academy of Neurology, April 2005
Miami/USA

Flail arm syndrome: a clinical variant of amyotrophic lateral sclerosis.
XIIIth Meeting of the European Neurological Society, June 2003
Istanbul/Turkey

Pathological crying as the initial presenting symptom in amyotrophic lateral sclerosis.
XIIIth Meeting of the European Neurological Society, June 2003
Istanbul/Turkey

Symptomatic care in ALS
Basler ALS Symposium, March 2003
Basel/Switzerland

Predictive value of T2-lesion volume for the natural course of multiple sclerosis.
Meeting of the Polish Neurological Society, September 200
Poznan/Poland

Rapid progressive, sensory-motor demyelinating neuropathy.
Xth International Neuromuscular Congress, July 2002
Vancouver/Canada

Ice pack test for myasthenia gravis: a simple, noninvasive and safe diagnostic method.
Xth International Neuromuscular Congress, July 2002
Vancouver/Canada

The natural course of multiple sclerosis: predictive value of lesion volume in T2-weighted brain MRI.
XIIth Meeting of the European Neurological Society, June 2002
Berlin/Germany

Necrotising  vasculitis and isotretinoin.
XIIth Meeting of the European Neurological Society, June 2002
Berlin/Germany

Wissenschaftliche Publikationen in der PubMed-Datenbank.